Company Overview 2Q 2022 © 2022 Salarius Pharmaceuticals, Inc. Non Confidential Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statement in this presentation that is not a historical fact is a forward-looking statement. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication o ...

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Q2 2022 Earnings Conference Call August 8, 2022 11:00 AM ET Company Participants Kim Golodetz - Senior Vice President, Principal, LHA Investor Relations David Arthur - Director and CEO Mark Rosenblum - Chief Financial Officer Dr. Daniela Santiesteban - Director, Protein Degradation, Development Conference Call Participants Ahu Demir - Ladenburg Operator Welcome to the Salarius Pharmaceuticals Second Quarter 2022 Financial Results and Business Update Conference Ca ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-36812 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (State or other ju ...

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Q1 2022 Earnings Conference Call May 12, 2022 5:00 PM ET Company Participants Daniel Kontoh-Boateng - Investor Relations David Arthur - Chief Executive Officer Mark Rosenblum - Chief Financial Officer Nadeem Mirza - Senior Vice President, Clinical Development Daniela Santiesteban - Director, Corporate Development Conference Call Participants Ahu Demir - Ladenburg Hunter Diamond - Diamond Equity Operator Good day, and thank you for standing by. Welcome to the Firs ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-36812 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (State or other j ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ———————–––––————————— FORM 10-K ———————————— (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-36812 —————————————— SALARIUS PHARMACEUTICALS, INC. (previously known as Flex P ...

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Q4 2021 Earnings Conference Call March 10, 2022 5:00 PM ET Company Participants Jason Rando - Investor Relations David Arthur - Chief Executive Officer Mark Rosenblum - Chief Financial Officer Nadeem Mirza - Senior Vice President, Clinical Development Daniela Santiesteban - Director, Corporate Development Conference Call Participants Ahu Demir - Ladenburg Thalmann Hunter Diamond - Diamond Equity Operator Good day and thank you for standing by. Welcome to Q4 2021 ...

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Q3 2021 Earnings Conference Call November 4, 2021 5:00 PM ET Company Participants Jason Rando - Tiberend Strategic Advisors David Arthur - Director, CEO Mark Rosenblum - CFO Nadeem Mirza - Senior Vice President, Clinical Development Daniela Santiesteban - Director of Corporate Development Conference Call Participants Ahu Demir - Ladenburg Aydin Huseynov - Benchmark Mike King - HC Wainwright Hunter Diamond - Diamond Equity Operator Thank you for standing by. And w ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-36812 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (State or oth ...

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Q2 2021 Earnings Conference Call August 5, 2021 10:00 AM ET Company Participants Jason Rando - Investor Relations, Executive Vice President, Chief Operating Officer, Tiberend Strategic Advisors David Arthur - Director & Chief Executive Officer Mark Rosenblum - Chief Financial Officer Nadeem Mirza - Senior Vice President, Clinical Development Daniela Santiesteban - Director, Corporate Development Conference Call Participants Aydin Huseynov - Benchmark Hunter Diamo ...